Targeting RhoA/Rho Kinase and p21-Activated Kinase Signaling to Prevent Cancer Development and Progression

被引:26
|
作者
Chang, Yu-Wen E. [1 ]
Bean, Ronald R. [1 ]
Jakobi, Rolf [1 ]
机构
[1] Kansas City Univ Med & Biosci, Kansas City, MO 64106 USA
关键词
Cancer invasion; metastasis; RhoA; Rho kinase; ROCK; p21-activated kinase; PAK; adherens junctions; cell motility; apoptosis; anoikis; SQUAMOUS-CELL CARCINOMA; GTP-BINDING PROTEIN; GERANYLGERANYLTRANSFERASE-I INHIBITOR; ANCHORAGE-INDEPENDENT GROWTH; HUMAN PANCREATIC-CANCER; RHO-GTPASES; EPITHELIAL-CELLS; TUMOR-CELLS; GENE-EXPRESSION; GAMMA-PAK;
D O I
10.2174/157489209788452830
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Elevated RhoA/Rho kinase and p21-activated kinase signaling have been shown to promote cancer development and metastasis and have drawn much attention as potential targets of anti-cancer therapy. Elevated RhoA and Rho kinase activity promote cancer cell invasion and eventually lead to metastasis by disrupting E-cadherin-mediated adherens junctions and degradation of the extracellular matrix. Elevated p21-activated kinase activity promotes invasion by stimulating cell motility but also promotes cancer cell survival and growth. In this review we describe normal functions of RhoA/Rho kinase and p21-activated kinase signaling, mechanisms that lead to constitutive activation of RhoA/Rho kinase and p21-activated kinase pathways, and processes by which constitutive RhoA/Rho kinase and p21-activated kinase activity promote cancer development and progression to more aggressive and metastatic phenotypes. In addition, we summarize relevant patents on RhoA/Rho kinase and p21-activated kinase as targets of anti-cancer therapy and discuss the clinical potential of different approaches to modulate RhoA/Rho kinase and p21-activated kinase signaling.
引用
收藏
页码:110 / 124
页数:15
相关论文
共 50 条
  • [1] p21-activated kinase signaling in breast cancer
    Gururaj, AE
    Rayala, SK
    Kumar, R
    BREAST CANCER RESEARCH, 2005, 7 (01) : 5 - 12
  • [2] p21-activated kinase signaling in breast cancer
    Anupama E Gururaj
    Suresh K Rayala
    Rakesh Kumar
    Breast Cancer Research, 7
  • [3] p21-activated kinase 4 promotes breast cancer initiation and progression
    Costa, T.
    Zhuang, T.
    Zhao, M.
    Li, Z.
    Rabenhorst, U.
    Olofsson, H.
    Varas, P. Hernandez
    Lorent, J.
    Strmblad, S.
    MOLECULAR BIOLOGY OF THE CELL, 2014, 25
  • [4] Overexpression of p21-activated kinase 1 promotes endometrial cancer progression
    Lu, Wen
    Qu, Jun-Jib
    Li, Bi-Lan
    Lu, Cong
    Yan, Qin
    Wu, Xiao-Mei
    Chen, Xiao-Yu
    Wan, Xiao-Ping
    ONCOLOGY REPORTS, 2013, 29 (04) : 1547 - 1555
  • [5] Targeting P21-Activated Kinase-1 for Metastatic Prostate Cancer
    Somanath, Payaningal R.
    Chernoff, Jonathan
    Cummings, Brian S.
    Prasad, Sandip M.
    Homan, Harvey D.
    CANCERS, 2023, 15 (08)
  • [6] A role for p21-activated kinase 7 in the development of gastric cancer
    Gu, Jun
    Li, Keqiang
    Li, Maolan
    Wu, Xiangsong
    Zhang, Lin
    Ding, Qichen
    Wu, Wenguang
    Yang, Jiahua
    Mu, Jiasheng
    Wen, Hao
    Ding, Qian
    Lu, Jianhua
    Hao, Yuan
    Chen, Lei
    Zhang, Wenjie
    Li, Songgang
    Liu, Yingbin
    FEBS JOURNAL, 2013, 280 (01) : 46 - 55
  • [7] P21-activated kinase 1 and breast cancer
    Rakesh Kumar
    中华乳腺病杂志(电子版), 2010, 4 (05) : 544 - 553
  • [8] p21-Activated kinase 5: A pleiotropic kinase
    Wen, Yi-Yang
    Wang, Xiao-Xia
    Pei, Dong-Sheng
    Zheng, Jun-Nian
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (24) : 6636 - 6639
  • [9] Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer-Opportunities, Challenges, and Limitations
    Eswaran, Jeyanthy
    Li, Da-Qiang
    Shah, Anil
    Kumar, Rakesh
    CLINICAL CANCER RESEARCH, 2012, 18 (14) : 3743 - 3749
  • [10] p21-Activated kinase 4 promotes prostate cancer progression through CREB
    Park, M-H
    Lee, H-S
    Lee, C-S
    You, S. T.
    Kim, D-J
    Park, B-H
    Kang, M. J.
    Heo, W. D.
    Shin, E-Y
    Schwartz, M. A.
    Kim, E-G
    ONCOGENE, 2013, 32 (19) : 2475 - 2482